Romidepsin, a histone deacetylase inhibitor, was investigated in combination with CHOP in a randomised phase III trial conducted by the LYSA group for PTCL, excluding ALK-positive ALCL [36]. The gene discussed is ALK; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.